Clinical Trials Logo

Vascular Diseases clinical trials

View clinical trials related to Vascular Diseases.

Filter by:

NCT ID: NCT01279642 Completed - Clinical trials for Peripheral Vascular Disease

Placement of Peripherally Inserted Central Venous Catheters (PICC) in Children Guided by Ultrasound

Start date: August 2008
Phase: N/A
Study type: Interventional

Aimed to compare the success in the peripheral intravenous puncture (PIP), progression and placement of PICC in children, according to the use of Doppler vascular ultrasound (DVUS) or traditional method; to identify the influence of the DUVS in the time expended to PICC placement. Methods: Clinical, randomized and controlled trial conducted after ethical merits of research endorsement and the obtaining of consent for those responsible for the children. The sample, calculated in 42 PICC to obtain a power of 0,85, was distributed randomly into two groups, experimental group (EG) and controlled group (CG). To the statistical analyzes Pearson Chi-square, Fisher's Exact Tests, Generalization of Fischer's Exact and Mann-Whitney tests was applied (5%). Of the 42 catheters, 21 (50.0%) were implemented in EG and 21 (50.0%) in CG. The PIP was obtained in the first attempt in 90.5% of the punctures of the EG and in 47.6% of the GC, (p=0.003). PICC were implanted successfully in 18 (85.7%) children of GE and 11 (61.1%) of CG (p = 0.019). The median of the time spent to the procedure was significantly higher (p=0.001) in CG (50 minutes) when compared to EG (median 20 minutes).

NCT ID: NCT01278745 Terminated - Clinical trials for Cardiac Allograft Vasculopathy

Prevention of Cardiac Allograft Vasculopathy Using Rituximab (Rituxan) Therapy in Cardiac Transplantation

Start date: September 2011
Phase: Phase 2
Study type: Interventional

All people who have a heart transplant are at risk for developing cardiac allograft vasculopathy (CAV). CAV means narrowing of the heart transplant vessels, which is associated with poor heart transplant function. People who develop antibodies after transplant have a higher risk of developing CAV. Infections, high cholesterol, and rejection also increase the risk of developing CAV. People who develop CAV usually have to receive another transplant.

NCT ID: NCT01275092 Completed - Clinical trials for Coronary Artery Disease

Evaluation of the Safety and Effectiveness of the CorPath 200 System in Percutaneous Coronary Interventions (PCI)

PRECISE
Start date: January 2011
Phase: Phase 2
Study type: Interventional

The objective of this study is to evaluate the safety and effectiveness of the clinical and technical performance of the CorPath® 200 System in the delivery and manipulation of coronary guidewires and stent/balloon systems for use in percutaneous coronary interventions (PCI).

NCT ID: NCT01271426 Completed - Clinical trials for Polypoidal Choroidal Vasculopathy

Response to Ranibizumab in Polypoidal Choroidal Vasculopathy (PCV)and SNPs

Start date: April 2008
Phase: N/A
Study type: Observational

To determine whether complement factor H (CFH) and age-related maculopathy susceptibility 2 (ARMS2) genotypes have a pharmacogenetic effect on the treatment of polypoidal choroidal vasculopathy (PCV) with ranibizumab.

NCT ID: NCT01266148 Completed - Clinical trials for Renal Function and Chronic Allograft Vasculopathy

SCHEDULE - Scandinavian Heart Transplant Everolimus de Novo Study With Early Calcineurin Inhibitor (CNI) Avoidance

SCHEDULE
Start date: November 2009
Phase: Phase 4
Study type: Interventional

A controlled, randomized, open-label, multicenter study evaluating if early initiation of everolimus and early elimination of cyclosporine in de novo heart transplant recipients can improve long-term renal function and slow down the progression of chronic allograft vasculopathy

NCT ID: NCT01263665 Completed - Clinical trials for Peripheral Vascular Diseases

Evaluation of the 25 Centimeter (cm) GORE® VIABAHN® Endoprosthesis

Start date: December 2010
Phase: N/A
Study type: Interventional

The purpose of this study is to confirm the safety and performance of the 25 cm GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface when used in the Superficial Femoral Artery.

NCT ID: NCT01249027 Completed - Clinical trials for Coronary Artery Disease

XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval, Single-Arm Study

XV CHINA SAS
Start date: November 2010
Phase:
Study type: Observational

This is a prospective, observational, single-arm, open-label, multicenter, postapproval registry study in China. The purpose of this study is to: - Evaluate the continued safety and effectiveness of the XIENCE V EECSS in a cohort of real-world patients receiving the XIENCE V EECSS during commercial use - Evaluate patient compliance to dual antiplatelet therapy (DAPT)

NCT ID: NCT01248117 Recruiting - Clinical trials for Polypoidal Choroidal Vasculopathy

Safety Study of High-Dose Ranibizumab for Polypoidal Choroidal Vasculopathy

PEARL2
Start date: November 2010
Phase: Phase 1/Phase 2
Study type: Interventional

Monthly, continuous anti-vegf therapy for patients presenting with active polypoidal choroidal vasculopathy. Two arms, treatment naive and previously treated with an FDA approved anti-VEGF therapy, will be randomized and dosed with open label 2.0mg ranibizumab.

NCT ID: NCT01239901 Completed - Sickle Cell Disease Clinical Trials

Iron Mediated Vascular Disease in Sickle Cell Anemia Patients

Start date: December 2009
Phase:
Study type: Observational

The purpose of this research study is to determine the frequency and severity of iron overload in patients with Sickle Cell Anemia and its relationship to blood vessel function. The investigators hypothesize that intermittent transfusions that these patients receive during hospitalizations produces significant iron overload and impairs blood vessel relaxation.

NCT ID: NCT01235312 Completed - Clinical trials for Cutaneous Microcirculation in Vascular Diseases

Microcirculatory Mapping of the Aging Hand and Foot

Start date: September 2010
Phase: N/A
Study type: Observational

Currently, dorsal hand rejuvenation is an upcoming issue as patients seek plastic surgeons to address this highly visible area, although no specific statistics concerning the number of patients undergoing dorsal hand rejuvenation have been published yet. The solitary use of fillers, fat, sclerotherapy, skin excision, resurfacing and combinations of the above mentioned therapies have been reported in the literature, but still there is a lack of scientific literature about functional microcirculation of the dorsum of the hand. Furthermore, there is a lack of scientific data about functional microcirculation of the plantar foot in healthy subjects compared to patients suffering from Diabetes mellitus or peripheral arterial occlusive disease. Consequently, the aim of this study is the evaluation of the functional microcirculation of hands and feet in healthy subjects as well as patients suffering from the above mentioned diseases.